Insider Buying: Hyperion DeFi (NASDAQ:HYPD) CFO Acquires 27,950 Shares of Stock

Hyperion DeFi, Inc. (NASDAQ:HYPD) CFO David Knox bought 27,950 shares of the firm’s stock in a transaction on Wednesday, December 31st. The stock was acquired at an average cost of $3.59 per share, with a total value of $100,340.50. Following the completion of the transaction, the chief financial officer directly owned 327,950 shares of the company’s stock, valued at approximately $1,177,340.50. This represents a 9.32% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Hyperion DeFi Stock Performance

HYPD opened at $3.58 on Monday. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.25 and a current ratio of 2.25. The company has a market cap of $29.25 million, a PE ratio of -0.89 and a beta of 2.69. The stock has a 50-day moving average of $4.54 and a 200-day moving average of $7.57. Hyperion DeFi, Inc. has a 52-week low of $0.85 and a 52-week high of $17.18.

Hyperion DeFi (NASDAQ:HYPD) last posted its earnings results on Friday, November 14th. The company reported $0.05 earnings per share for the quarter. The company had revenue of $0.36 million during the quarter. As a group, equities research analysts forecast that Hyperion DeFi, Inc. will post -41.6 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

HYPD has been the topic of several recent analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Hyperion DeFi in a report on Wednesday, October 8th. Zacks Research upgraded Hyperion DeFi to a “hold” rating in a research note on Monday, December 29th. Wall Street Zen raised Hyperion DeFi from a “sell” rating to a “hold” rating in a report on Saturday, November 22nd. Cantor Fitzgerald started coverage on Hyperion DeFi in a report on Tuesday, December 16th. They set an “overweight” rating and a $4.00 price target for the company. Finally, Chardan Capital set a $7.75 price objective on Hyperion DeFi and gave the company a “buy” rating in a research report on Wednesday, December 24th. Two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $4.58.

About Hyperion DeFi

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.